OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Long-Lasting Immunity Against SARS-CoV-2: Dream or Reality?
Daniel Gussarow, Agnes Bonifacius, Anne Cossmann, et al.
Frontiers in Medicine (2021) Vol. 8
Open Access | Times Cited: 18

Showing 18 citing articles:

SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity
Stefan Pilz, Verena Theiler‐Schwetz, Christian Trummer, et al.
Environmental Research (2022) Vol. 209, pp. 112911-112911
Open Access | Times Cited: 232

SARS-CoV-2—The Role of Natural Immunity: A Narrative Review
Sara Diani, Erika Leonardi, Attilio Cavezzi, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 21, pp. 6272-6272
Open Access | Times Cited: 33

Immune correlates of protection for SARS-CoV-2, Ebola and Nipah virus infection
Beatriz Escudero-Pérez, Philip Lawrence, Javier Castillo‐Olivares
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 16

SARS-CoV-2 - The Role of Natural Immunity: A Narrative Review
Sara Diani, Erika Leonardi, Attilio Cavezzi, et al.
(2022)
Open Access | Times Cited: 13

Factors influencing the immune response over 15 months after SARS‐CoV‐2 infection: A longitudinal population‐wide study in the Faroe Islands
Maria Skaalum Petersen, Laura Pérez‐Alós, José Juan Almagro Armenteros, et al.
Journal of Internal Medicine (2022) Vol. 293, Iss. 1, pp. 63-81
Open Access | Times Cited: 12

Rapid Manufacturing of Highly Cytotoxic Clinical-Grade SARS-CoV-2-specific T Cell Products Covering SARS-CoV-2 and Its Variants for Adoptive T Cell Therapy
Agnes Bonifacius, Sabine Tischer‐Zimmermann, Maria Michela Santamorena, et al.
Frontiers in Bioengineering and Biotechnology (2022) Vol. 10
Open Access | Times Cited: 10

Design and performance characteristics of the Elecsys anti-SARS-CoV-2 S assay
Karin Taffertshofer, Mirko Walter, Peter Mackeben, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 10

Immune Profiling Uncovers Memory T-Cell Responses with a Th17 Signature in Cancer Patients with Previous SARS-CoV-2 Infection Followed by mRNA Vaccination
Miriam Echaide, Ibone Labiano, Marina Delgado, et al.
Cancers (2022) Vol. 14, Iss. 18, pp. 4464-4464
Open Access | Times Cited: 9

Reduced humoral but stable cellular SARS-CoV-2-specific immunity in liver transplant recipients in the first year after COVID-19
Theresa Kirchner, S. Heinrich, Agnes Bonifacius, et al.
PLoS ONE (2022) Vol. 17, Iss. 11, pp. e0276929-e0276929
Open Access | Times Cited: 8

Coronavirus Disease 2019 (COVID-19) Reinfection Rates in Malawi: A Possible Tool to Guide Vaccine Prioritisation and Immunisation Policies
Master Chisale, Frank Watson Sinyiza, Paul Uchizi Kaseka, et al.
Vaccines (2023) Vol. 11, Iss. 7, pp. 1185-1185
Open Access | Times Cited: 4

Persistence of T-Cell Immunity Responses against SARS-CoV-2 for over 12 Months Post COVID-19 Infection in Unvaccinated Individuals with No Detectable IgG Antibodies
Vassiliki Pitiriga, Myrto Papamentzelopoulou, Kanella E. Konstantinakou, et al.
Vaccines (2023) Vol. 11, Iss. 12, pp. 1764-1764
Open Access | Times Cited: 4

SARS-CoV-2 Reinfections: Overview of Efficacy and Duration of Natural and Hybrid Immunity
Stefan Pilz, Verena Theiler‐Schwetz, Christian Trummer, et al.
SSRN Electronic Journal (2022)
Closed Access | Times Cited: 5

Coronavirus spike protein-based vaccines. Vaccine delivery systems
Akmal M. Asrorov, Mirzakamol S. Ayubov, Bin Tu, et al.
Medicine in Drug Discovery (2024), pp. 100198-100198
Open Access

Rationale for combined therapies in severe-to-critical COVID-19 patients
Aitor Gonzaga, Etelvina Andreu, Luis Blasco, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 1

SUPPLEMENT 11 SEEC & 31 IMAB, Section Medicine

Journal of IMAB - Annual Proceeding (Scientific Papers) (2022) Vol. 27, Iss. Supplement
Open Access | Times Cited: 1



Journal of IMAB - Annual Proceeding (Scientific Papers) (2022) Vol. 27, Iss. Supplement
Open Access

Page 1

Scroll to top